Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer

Genes Chromosomes and Cancer

Volumn 17, Issue 1, 1996, Pages 14-20

  An, Han Xiang ^a,b   Niederacher, Dieter ^a,c   Picard, Frauke ^a   Van Roeyen, Claudia ^a   Bender, Hans Georg ^a   Beckmann, Matthias Wilhelm ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELISM; ARTICLE; BREAST CANCER; CARCINOGENESIS; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE LOCUS; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029847288     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.3.CO;2-Y     Document Type: Article

References (35)

1. Ausubel FM, Brent R, Moore DD, Seidman JG, Smith JA, Struhl K (1995) Current Protocols in Molecular Biology. New York: John Wiley and Sons, Inc.
2. Beckmann MW, Toney LJ, Scharl A, Fuchs-Young R, Greene GL, Holt JA (1992) Detection of Her-2/neu proto-oncogene protein p185erbB2 by a novel monoclonal antibody (MAB-145ww) in breast cancer membranes from estrogen and progesterone receptor assays. Eur J Cancer 28:322-326.
3. Beckmann MW, Picard F, An H-X, van Roeyen CRC, Mosny DS, Schnürch HG, Bender HG, Niederacher D (1996) Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer 73:1220-1226.
4. Berns EM, Klijn JG, Smid M, van Staveren IL, Gruis NA, Foekens JA (1995) Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer 72:964-967.
5. Black DM (1994) The genetics of breast cancer. Eur J Cancer 30A: 1957-1961.
6. Brenner AJ, Aldaz CM (1995) Chromosome 9p allelic loss and p16/ CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res 55:2892-2895.
7. Cairns P, Tokino K, Eby Y, Sidransky D (1994) Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 54: 1422-1424.
8. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:27-32.
9. Cawkwell L, Bell SM, Lewis FA, Dixon MF, Taylor GR, Quirke P (1993) Rapid detection of allele loss in colorectal tumors using microsatellites and fluorescent DNA technology. Br J Cancer 67: 1262-1267.
10. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR (1994) p16 Alterations and deletion mapping of 9p21-22 in malignant mesothelioma. Cancer Res 54:5547-5551.
11. Coleman A, Fountain JW, Nobori T, Olopade OI, Robertson G, Housman DE, Lugo TG (1994) Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res 54:344-348.
12. Devilee P, Cornelisse CJ (1994) Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1198:113-130.
13. Dreyling MH, Bohlander SK, Le Beau MM, Olopade OI (1995) Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood 86:1931-1938.
14. Dutrillaux B, Gerbault-Seureau M, Zafrani B (1990) Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid cases with few chromosome changes. Cancer Genet Cytogenet 49:203-217.
15. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646.
16. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y (1994) Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202:1426-1430.
17. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
18. Holland EA, Beaton SC, Edwards BG, Kefford RF, Mann GJ (1994) Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Oncogene 9:1361-1365.
19. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
20. Keen AJ, Knowles MA (1994) Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9:2083-20888.
21. Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R (1995) Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11:597-600.
22. Lindblom A, Skoog L, Rotstein S, Werelius B, Larsson C, Nordenskjold M (1993) Loss of heterozygosity in familial breast carcinomas. Cancer Res 53:4356-4361.
23. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A (1995) CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067.
24. Mead LJ, Gillespie MT, Irving LB, Campbell LJ (1994) Homozygous and hemizygous deletions of 9p centromeric to the interferon genes in lung cancer. Cancer Res 54:2307-2309.
25. Merlo A, Gabrielson E, Askin F, Sidransky D (1994) Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res 54:640-642.
26. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y (1994) Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397.
27. Neville EM, Stewart M, Myskow M, Donnelly RJ, Field JK (1995) Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. Oncogene 11:581-585.
28. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 238:753-756.
29. Pandis N, Jin Y, Gorunova L, Petersson C, Bardi G, Idvall I, Johansson B, Ingvar C, Mandahl N, Mitelman F (1995) Chromosome analysis of 97 primary breast carcinomas: Identification of eight karyotypic subgroups. Genes Chromosom Cancer 12:173-185.
30. Puig S, Ruiz A, Lazaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro JM, Estivill X (1995) Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. Am J Hum Genet 57:395-402.
31. Sakata K, Tamura G, Maesawa C, Suzuki Y, Terashima M, Satoh K, Eda Y, Suzuki A, Sekiyama S, Satodate R (1995) Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas. Jpn J Cancer Res 86:333-335.
32. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, Nakamura Y (1990) Allelotype of breast cancer: Cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 50:7184-7189.
33. Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK (1995) Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 55:2150-2157.
34. van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, Sidransky D (1994) Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54:1156-1158.
35. ink4) in human breast carcinomas. Cancer Res 54:5262-5264.